← SynDRA
REFAMETINIB
SynDRA canonical compound SYN0024394 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAP2K2 |
|---|
| Mechanism of action | MEK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MEK inhibitor
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
Cross-references
Synonyms
- BAY-86-9766
- Rdea119
- BAY-869766
- BAY-8697661
- BAY86-9766
- BAY869766
- BAY8697661
- RDEA-119
- BAY 86-9766
- RDEA119
- UNII-JPX07AFM0N
- Refametinib (RDEA119, Bay 86-9766)
- JPX07AFM0N
- (S)-N-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
- N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
- Refametinib [INN]
- BAY 8697661
- 3e8n
- Refametinib R enantiomer
- Refametinib (RDEA119)
- SCHEMBL345333
- Refametinib (BAY86-9766)
- BAY 86-97661
- Refametinib; RDEA119
- REFAMETINIB [WHO-DD]
- GTPL7942
- CHEMBL1236682
- DTXSID40238961
- BDBM520650
- EX-A2481
- MFCD18633256
- NSC800864
- s1089
- ZINC39187987
- AKOS025401896
- CCG-270103
- CS-1818
- DB06309
Look up REFAMETINIB in the interactive SynDRA portal →